BUY Info Edge (India) Limited — IDBI Capital
byIDBI CapitalHorizon: NA (inferred Swing (≤2wk))5 Nov 2026via IDBI Capital Research Calls Telegram
Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.
AI Assessment
Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.
2 other SEBI-registered advisors have active swing BUY calls on this stock, all issued in the last 14 days
Advisor consensus · same horizon·6 Nov · today
Info Edge Q4 Review: Brokerages Stay Bullish, See AI Products Driving Growth; Check Target Price, Potential Upside
NewsNdtv-Profit·29 Oct · 1w ago
Info Edge (India) Appoints Sanjeev Bikhchandani As Group CEO; Q2 Profit Rises 8% QoQ To Rs 480 Crore
NewsNdtv-Profit·28 Oct · 1w ago
Info Edge reported Q2FY27 billings growth of 12.8% YoY and operating PBT growth of 29.8%, with 99acres billings growth accelerating to 21.2%.
NSE · Press Release·28 Oct · 1w ago
Info Edge's subsidiary, Startup Investments (Holding) Ltd., will invest Rs 5 crore in Bizcrum Infotech (Bijnis) to acquire a 20.12% stake on a fully diluted basis.
BSE · Company Update·23 Oct · 2w ago
Info Edge NAUKRI Q2 FY27 Earnings Call Key Highlights
NewsGoogle News·30 Oct · 6d ago
Info Edge approved the divestment of its stakes in Medcords Healthcare and Unnati Online, and an investment of Rs 150 crore in its wholly-owned subsidiary, Redstart Labs.
NSE · Acquisition·28 Oct · 1w ago
Info Edge approved the divestment of its stakes in Medcords Healthcare Solutions and Unnati Online, and an investment of Rs 150 crore in its wholly-owned subsidiary, Redstart Labs.
BSE · Company Update·28 Oct · 1w ago
Info Edge (India) Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.
NSE · Outcome of Board Meeting·28 Oct · 1w ago
Naukri brand parent Info Edge shares dip after ₹3 per share dividend move | Check payment, record date, history, yield
NewsLivemint·28 Oct · 1w ago
Hitesh Oberoi is transitioning from his role as MD & CEO after 27 years, with Sanjeev Bikhchandani assuming an expanded executive leadership role.
NSE · Press Release·28 Oct · 1w ago
Mr. Hitesh Oberoi is transitioning from his role as MD & CEO to a Non-Executive Non-Independent Director.
BSE · Company Update·28 Oct · 1w ago
Mr. Hitesh Oberoi is transitioning from his role as MD & CEO to a Non-Executive Non-Independent Director.
BSE · Company Update·28 Oct · 1w ago
Mr. Hitesh Oberoi is transitioning from his role as MD & CEO to a Non-Executive Non-Independent Director position.
BSE · Company Update·28 Oct · 1w ago
Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.
Other calls on Info Edge (India)
- BUY — Deven Mehata, IDBI Capital Markets and Securities6 Nov 2026 · ~2 weeks · target ₹1,315 · Active
- BUY — Akshay Bhagwat, JM Financial5 Nov 2026 · ~2 weeks · target ₹1,260 · Active
- BUY — Citigroup29 Oct 2026 · ~1 year · target ₹1,500 · Active
- BUY — Goldman Sachs29 Oct 2026 · ~1 year · target ₹1,430 · Active
- BUY — Jefferies India29 Oct 2026 · ~1 year · target ₹1,500 · Active
More from IDBI Capital
- BUY Alkem Laboratories6 Nov 2026 · ~2 weeks · target ₹5,460 · Active
- BUY Onesource Specialty Pharma6 Nov 2026 · ~2 weeks · target ₹1,735 · Active
- BUY Sun Pharmaceutical Industries6 Nov 2026 · ~2 weeks · target ₹1,925 · Active
- BUY Vijaya Diagnostic Centre6 Nov 2026 · ~2 weeks · target ₹1,575 · Active
- BUY Rolex Rings6 Nov 2026 · ~1 year · target ₹241 · Active

